Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Heliospectra

Related articles:
2/27/2024 6:21:29 AM - Heliospectra: Rebound in the Duch market boosts strong growth potential - Redeye - Redeye has revised its estimates in light of Heliospectra’s Q4 2023 report, which was slightly softer than expected regarding sales and order intake. Yet, we expect a rebound in the Dutch market during 2024 and expect Heliospect to capitalise on it with its new product platform. However, due to softer-than-expected order intake in Q4 2023 and seasonal effects, we foresee a softer first half followed by a stronger second half in 2024. Our Base case remains intact at SEK1.4 per share.
2/23/2024 8:34:16 AM - Heliospectra Q4 2023: Softer than expected - Redeye - Redeye leaves its initial comments on Heliospectras’ Q4 2023 report, in which the figures were slightly softer than expected. However, OPEX was well below our forecast, indicating that the cost reduction program continues to yield results. We will probably revise our short-term forecasts downward on the back of the slower-than-expected order intake in the quarter.
1/12/2024 7:15:51 AM - Nasdaq inför dagliga auktioner för 15 bolag på First North med svag likviditet - Börsoperatören Nasdaq inför med start den 18 januari en ny modell med dagliga aktioner som omfattar 15 bolag på First North i Stockholm och Helsingfors. Syftet är att försöka att skapa bättre likviditet.
11/22/2023 10:31:39 AM - Heliospectra: Bridge loan of SEK10m - Redeye - Redeye comments on Heliospectra’s bride loan, announced last evening. The bridge loan totals SEK10m, with the primary stakeholders being Weland Stål AB, Agartha AB, and Corespring New Technology AB as lenders. We reiterate our Base case of SEK1.4 per share.
10/30/2023 6:04:39 AM - Heliospectra: Continued headwinds on the Dutch market - Redeye - Redeye has revised our estimates in light of Heliospectra’s Q3’23 report, which showed a suppressed top-line and order intake due to macroeconomic challenges, falling below our expectations. Meanwhile, Heliospectra continues to run a very lean cost base. Our cautiously optimistic outlook, as indicated in the previous quarter, remains unchanged as we see potential opportunities outside the Dutch market, particularly within the ornamental segment. The adjustments to our fair value range have been influenced by the impact of increasing interest rates and forecast revisions, resulting in a new Base case of SEK1.4 (SEK1.9) per share.
10/27/2023 7:51:55 AM - Heliospectra: Softer top-line and order intake than expected - Redeye - Redeye concludes that Heliospectra’s Q3 report was somewhat weaker than anticipated in terms of both top-line revenue and order intake. Nevertheless, the gross margin and OPEX outperformed our expectations. As a result, we anticipate making slight adjustments to our short-term forecast and fair value range.
8/29/2023 5:37:26 AM - Heliospectra: Mixed outlook - Redeye - Redeye provides an update following Heliospectra’s Q2’23 report. We find the margin improvements, combined with a stronger-than-expected top line, to be encouraging. However, order intake fell short of our expectations, implying a weaker Dutch market and a mixed outlook in the near term. We have made a few minor changes to our near-term estimates. Our fair value range, however, remains unchanged, with a base case of SEK1.9 per share.
8/25/2023 7:52:02 AM - Heliospectra Q2 2023: First impression - Redeye - Redeye provides its initial take on Heliospectra’s Q2’23 report, noting that sales surpassed our expectations. However, the order intake was below expectations, but the cost structure remained in line with our estimates. Consequently, we anticipate minor revisions to our near-term forecast and fair value range.
5/3/2023 8:57:25 AM - Heliospectra: Transitory quarter with secured growth capital - Redeye - Redeye provides an update following Heliospectra’s Q1’23 report, where an increased gross margin, a well-controlled cost basis, and management’s anticipation of robust order intake in Q2’23 support an optimistic outlook. Sales and order intake came in slightly lower than expected. Hence, we have made a few minor changes to our near-term estimates. Our fair value range, however, remains unchanged, with a base case of SEK1.9 per share.
4/28/2023 8:17:08 AM - Heliospectra Q1 2023: Initial take - Redeye - Redeye provides its initial take on Heliospectra’s Q1’23 report, stating that sales and order intake were weaker than our forecast. However, the outlook remains positive, and the cost base is well-contained. As a result, we anticipate only marginal adjustments to our near-term estimates and likely leave our fair value range intact.
4/12/2023 5:04:53 AM - Heliospectra: Outcome of rights issue - Redeye - Redeye comments on the outcome of Heliospectra's rights issue, which received a subscription rate of c83%. In our previous Base case, we had already factored in a rights issue, but the actual outcome resulted in a lower level of dilution. As a result, we have made slight upward revisions to our valuation, with a new Base case of SEK1.9 (1.7) per share.
3/14/2023 9:42:42 AM - Heliospectra: Announces a 77% secured rights issue - Redeye - Redeye comments on Heliospectra’s rights issue, announced earlier this morning. Upon full subscription, the company will receive cSEK26m to expand on the European market. The rights issue is secured to 77% by the four main owners, corresponding to their pro rata shares. We have already considered a rights issue in our valuation; therefore, we reiterate our base case of SEK1.7 per share.
3/2/2023 7:01:33 AM - Heliospectra Q4 2022: Positive outlook and permanent CEO appointed - Redeye - Redeye provides an update following Heliospectra’s amended Q4'22 report, in which order intake was significantly increased from SEK7.7m to 14.3m. We further view the appointment of Bonny Heeren as permanent CEO positively, as he has been the driving force behind the cost-cut program and the transformation of Heliospectra in 2022. Heliospectra enters 2023 with a lighter cost base, a new product range, and the ambition to reach break even by the end of 2023. We have made some minor adjustments to our estimates, lowering expectations for H1’23 but increasing our mid-term expectations. However, our valuation remains intact with a base case fair value at SEK1.7 per share.
2/24/2023 9:41:47 AM - Heliospectra Q4 2022 initial take: Ambition to reach break-even by the end of 2023 - Redeye - Redeye provides its initial thoughts on Heliospectra’s fourth-quarter report, which showed net sales of SEK 10.0 million. 2022 was a year of transition for Heliospectra, and this year is meant to be a turning point. We see some early indications in the Q4 report with well-managed cost control and improved sales. Combined with the news released earlier today, expanding the product portfolio with the new MITRA flex and the ambition to reach break-even by the end of 2023 boost our confidence in the transition.
11/11/2022 3:36:19 PM - Heliospectra- First Smart LED Light Solution Order - Redeye - Redeye endorses today’s news from Heliospectra, an order of USD780,000 from an American AgTech company. The order is the first for Heliospectra’s smart LED solution. We were not anticipating any orders for the new solution until Q1 2023 and view this as a potential sign of product-market fit.
10/25/2022 7:04:27 AM - Heliospectra: Transformation in progress - Redeye - Redeye adjusts our near-term forecasts and our valuation following the Q3 report and the recent share issuance. We notice clear signs of transformation with solid cost control, reorganization, new distribution strategy, and encouraging order intake in Q3. Furthermore, we are reassured by the credit facility from the main owners, but we lower our valuation on the possibility of a new set-off issue in early 2023 and on back of the dilution from the latest set-off issue.
10/21/2022 12:58:10 PM - Heliospectra Q3 2022: Encouraging order intake - Redeye - Redeye leaves its initial take on Heliospectra’s Q3 report, which came in with a firm order intake of SEK 9.2m. This year has been dedicated to product development, cost-savings initiatives and restructuring to become more robust in 2023 with best-in-class product offerings for Smart Farming. Meanwhile, Heliospectra continues to show solid cost control, and the encouraging order intake in Q3 further adds confidence to the undergoing transition.
9/5/2022 5:32:47 AM - Heliospectra: Preparing for the next step - Redeye - Redeye is making some further adjustments to our near-term forecasts following a rather soft Q2 report. Modest sales and order bookings so far this year reflect the company’s current transition. We hope and expect to see better market traction in 2023, after the new product offering is launched later this year.
8/23/2022 2:16:24 PM - Heliospectra: Executing operational changes - VH Corp - * Lower sales than expected in Q2 due to ongoing strategic re-organization<br>* Well-positioned to take advantage of increasing energy prices<br>* We maintain our valuation interval of SEK 2.80 – 4.40 per share
8/19/2022 11:15:01 AM - Heliospectra Q2: First comment - Redeye - Redeye recognizes that Heliospectra currently is in a phase of transition. Consequently, we had no high expectations on recorded sales or order intake for the second quarter. We believe the company is doing solid progress and will be able to gain good market traction for its new offering for so called Smart Farming. Hopefully we will see some positive signs later this year. Meanwhile, we note that costs are well contained and finances are secured until Q1’23.
4/27/2022 7:30:06 AM - Heliospectra: In transition - VH Corp - * Disappointing turnover and order intake in Q1<br>* Strategic reorientation should pay off eventually<br>* We lower our fair value interval to SEK 2.80 – 4.40 (3.60 – 5.60) per share<br>Heliospectra’s report for Q1 2022 was a disappointment in terms of turnover<br>and order intake. This may have been inevitable, as the company finds itself<br>in the middle of a reorientation of strategy under the company’s new CEO,<br>Bonny Heeren. New starts often take time to produce results. This, together<br>with the economic challenges facing customers in greenhouse farming due to<br>high energy costs, has persuaded us to lower our revenue forecast for<br>Heliospectra, especially for the near term. Our revised valuation model points<br>to a fair value interval of SEK 2.80 – 4.40 per share, down from SEK 3.60 –<br>5.60 per share.
4/26/2022 5:36:56 AM - Heliospectra: Transitional Year - Redeye - Redeye is still optimistic about Heliospectra and the prospects for its new strategic direction as a system supplier within Smart Farming. 2022 is described as a transitional year, including refocus of the organization and finalizing some important development projects for the new customer offering. Fortunately, the company has received a new credit facility from its three main owners, securing financing until February 2023. We are only making minor adjustments to our forecasts and valuation, which still indicates some potential in the share.
4/22/2022 10:45:28 AM - Heliospectra Q1’22: First impression - Redeye - Redeye’s expectations on the Q1 numbers were rather modest as Heliospectra is in a transitional phase following its strategic shift. Sales and earnings are basically in line and gross margins surprisingly strong. We are encouraged to see that a credit facility has been secured that extends to February 2023. This will enable Helispectra to make the investments necessary to implement the new strategy. As for the very short-term outlook, we will most likely lower our forecasts a bit further on the back of slow order intake in the quarter.
3/3/2022 2:26:27 PM - Heliospectra: Strategic shift afoot - VH Corp - * Revenue higher but profits lower than expected<br>* New strategic shift announced during the quarter<br>* We maintain our valuation interval of SEK 3.60 – 5.60 per share
2/28/2022 6:46:06 AM - Heliospectra: Strategic Repositioning - Redeye - Redeye has made some revisions to near-term forecasts following Heliospectra’s shift in strategic direction, the Q4 report and other recent events. We believe the company’s ambition, to reposition itself from a supplier of LED lights to data-driven Smart Farming systems makes a lot of sense. It’s an attractive market expected to show strong growth in the foreseeable future. However, the transition probably means some negative impact on sales in the shorter term. Our new Base case fair value of ~SEK 2.4 per share is lower than previously, but still indicates a significant potential.
2/25/2022 9:23:01 AM - Heliospectra Q4’21: Initial comment - Redeye - Redeye’s expectations were almost in line with Heliospectra’s Q4 numbers, adjusted for non-recurring write-downs. We believe the company’s shift in strategic direction from a supplier of LED lights to a system supplier within Smart Farming is probably the right way to go. But we think it might have some short-term negative impact on sales growth. And with Q4 order intake on the low side we will most likely revise our near-term sales forecasts.
12/28/2021 1:08:29 PM - Heliospectra: CEO resigns - Redeye - Redeye was surprised by the recent announcement of CEO Ali Ahmadian’s sudden resignation. After five years as CEO, Ali will step down already on 31 December. The search and recruitment for a new CEO has been initiated. Meanwhile, Heliospectra’s board member Bonny Heeren, is taking the position as acting CEO.
11/30/2021 11:11:23 AM - Västra Hamnen Corporate Finance sänder live - Västra Hamnen Corporate Finance sänder live<br> Torsdag den 2:a december kl.10.30 är det dags för Västra Hamnen Corporate Finance Investerardag. Presentationerna sänds live via länken nedan. https://www.youtube.com/embed/312wtiq6ThU Preliminärt schema för dagen: 10:30: Västra Hamnen hälsar välkomna 10:40: ProstaLund 11:05: Heliospectra 11:30: Paus 11:40: Kjell Group 12:05: QLife 12:30: Lunch 13:10: SenzaGen 13:35: Newbury Pharmaceuticals 14:00: Paus 14:10: Movinn 14:35: RugVista 15:00: Fika 15:20: Advenica 15:45: Crunchfish 16:10: Paus 16:20: Clemondo 16:45: Polygiene Finwire Media hjälper små och medelstora företag samt fondbolag med investerarkommunikation.
11/1/2021 9:18:25 AM - Heliospectra: Launching biosensors next year - Redeye - Redeye is making some downward revisions in our forecasts and valuation but still sees an interesting potential in the share. Market conditions continue to be somewhat sluggish and Q3 sales were to some extent impacted by delays in shipments. Heliospectra is optimistic about the launch of the new biosensors in 2022, which it sees as the start of a completely new phase. Integrated sensors will probably be a major long-term growth driver for the company. We are lowering our near-term estimates and include an anticipated future rights issue in our valuation. Our new Base case fair value is just over SEK 3 per share.
10/27/2021 11:49:27 AM - Heliospectra: Headwinds in Q3 - VH Corp - * Both revenues and costs surprised towards the negative
10/22/2021 8:21:32 AM - Heliospectra Q3’21: Initial take - Redeye - Redeye was hoping for higher sales and order intake in the third quarter. According to Heliospectra, the market is still sluggish, primarily due to the ongoing impact from Covid. The company is still very optimistic about the launch of the new biosensors in 2022, which it sees as the start of a completely new phase for Heliospectra as a company. Reported EBIT of SEK -16m is heavily impacted by the provision of SEK 5.4m to cover additional costs related to the faulty MITRA fuse. Our financial forecasts for the current year will be revised on the back of weak Q3 numbers. We will be back shortly with updated estimates and valuation.
9/2/2021 8:40:28 AM - Heliospectra: Major growth opportunities ahead - Redeye - Redeye remains positive on the case as we see Heliospectra very well positioned to benefit from the long-term growth trends in the Aghort industry. Business has been impacted by the global pandemic and we now expect a general recovery in the market as conditions are improving. A stronger sales organization and improved offering, including the launch of biosensor systems in 2022, will in our view give excellent growth opportunities.
8/23/2021 5:25:15 AM - Heliospectra: Q2’21: Brief comment - Redeye - Redeye notes that Heliospectra’s Q2 numbers are on par with Q1 and mainly in line with our expectations. The market climate still appears to be somewhat hesitant, but we are quite certain the company will show growing sales over the next couple of years. The underlying demand for Heliospectras solutions will increase substantially for decades to come. A stronger sales organization and improved offering, including the launch of biosensor systems in 2022, will in our view give excellent growth opportunities. We are trimming our short-term estimates somewhat but are still confident in our long-term positive view.
4/29/2021 6:45:57 AM - Heliospectra: The Nectar Farms order is off - VH Corp - Heliospectra released its Q1 report last week, and while it was roughly as expected overall, there were both strong and weak spots in the details. A more attention-grabbing announcement came this week when the longdelayed order from Nectar Farms was finally cancelled. We never incorporated the full value of the order in our model as it appeared risky from the outset.
4/28/2021 12:12:03 PM - Heliospectra: Nectar Farms cancelled, estimates revised - Redeye - Redeye is adjusting its forecast following the recent news of Nectar Farms filing for liquidation. Heliospectra has now written off the order from Nectar Farms amounting to SEK 72m, which impacts Redeye's 2021-22 estimates significantly. The estimate revision also has bearing on the valuation and our Base case fair value is now around SEK 4.5 per share.
4/23/2021 12:45:59 PM - Heliospectra: Q1 first impression - Redeye - Redeye is encouraged to see higher order intake, despite continued challenging market conditions. Q1 numbers are basically in line with our expectations and we note that Opex have been well contained. Heliospectra is optimistic about the overall market trends and the company’s position, but the Covid-19 situation still poses restrictions on business. We are only making minor adjustments in our forecasts following the Q1 report.
3/19/2021 7:20:54 AM - Heliospectra: Ready to Grow - Redeye - Redeye reiterates its positive long-term stance to Heliospectra on the back of a year-end report overall in line with our expectations. With previous large signed orders on hold, while new ones seem to linger, we reduce our sales forecast for 2021 by 30%.
1/7/2021 7:14:18 AM - Heliospectra överlåter 930 000 teckningsoptioner till ledande befattningshavare och nyckelpersoner - Heliospectra har via dotterbolaget Heliospectra Personal överlåtit 930 000 teckningsoptioner av serie P03 till ledande befattningshavare och nyckelpersoner inom koncernen. Det framgår av ett pressmeddelande.
11/24/2020 8:13:31 AM - Heliospectras företrädesemission tecknades till 124 procent - Heliosprectras företrädesemission tecknades till 124 procent och bolaget tillförs således cirka 50,6 miljoner kronor för emissionskostnader. Det framgår av ett pressmeddelande.
11/10/2020 2:04:15 PM - Heliospectras belysningsteknik ska användas vid internationellt livsmedelsforskningsprojekt - Heliospectras belysningsteknik för växthus och kontrollerade odlingsmiljöer ska användas vid det internationella livsmedelsforskningsprojektet Realizing Increased Photosynthetic Efficiency. Det framgår av ett pressmeddelande.
11/5/2020 2:07:14 PM - Heliospectra får order i Kanada värd knappt 0,2 miljoner kanadensiska dollar - Heliospectra har fått en ny order från CRG Pharma i British Columbia, Kanada. Ordern är på bolagets Elixia Led-belysningslösning och värdet uppgår till 189 900 kanadensiska dollar. Beställningen kommer att levereras i fjärde kvartalet i år, enligt ett pressmeddelande.
10/28/2020 1:31:58 PM - Heliospectra i samarbete med Tokyo universitet kring inomhusodling av tomater - Heliospectra ska tillsammans med Tokyo universitet försöka odla tomater inomhus, enligt ett pressmeddelande.
10/27/2020 7:11:28 AM - Heliospectra förbättrar försäljningen i tredje kvartalet - Heliospectra redovisar en högre omsättning och lägre förlust i tredje kvartalet, jämfört med året innan. Orderingången är drygt 50 procent högre.
10/20/2020 11:21:14 AM - Heliospectra får ny order från kommersiell odlare i Massachusetts - Heliospectra har fått en ny order från ett företag som specialiserar sig på energieffektivisering, innovation och hållbarhet baserad i Marlborough i delstaten Massachusetts i USA. Kunden i sin tur agerar på uppdrag av en kommersiell cannabisodlare i Massachusetts. Ordervärdet uppgår till 238 500 dollar. Ordern är på Heliospectras LED-belysningslösning Mitra och beställningen levereras i fjärde kvartalet i år. Det framgår av ett pressmedelande.
9/28/2020 8:55:19 AM - Heliospectra kallar till extra stämma för att att besluta om nyemission - Aktieägarna i Heliospectra kallas till extra bolagsstämma tisdagen den 27 oktober i Göteborg.
9/28/2020 5:18:55 AM - Heliospectra tänker ta in drygt 50 miljoner kronor i fullt garanterad företrädesemission - Heliospectra tänker genomföra en fullt garanterad företrädesemission av units som tillför bolaget cirka 50,6 miljoner kronor före emissionskostnader. Det framgår av ett pressmeddelande.
9/25/2020 8:41:32 AM - Heliospectra får order värd 0,13 miljoner dollar från kanadensiska Origin Coast - Heliospectra har fått en ny order från kanadensiska Origin Coast. Ordervärdet är på strax över 132 000 dollar, enligt ett pressmeddelande.
9/1/2020 9:49:58 AM - Heliospectra får order värd 0,3 miljoner dollar - Heliospectra har fått en ny order från kanadensiska BBL Construction. Ordervärdet är på strax över 300 000 dollar, enligt ett pressmeddelande.
8/27/2020 12:24:22 PM - Heliospectra får uppföljningsorder av Marcella Property Group värd 87 920 dollar - Heliospectra tillkännager att företaget får ytterliggare en order från amerikanska Marcella Property Group uppgående till 87 920 dollar, vilket motsvarar cirka 770 000 svenska kronor.
8/21/2020 7:08:31 AM - Heliospectras rörelseförlust ökade under andra kvartalet - Heliospectra redovisar minskande omsättning under andra kvartalet jämfört med samma period året innan. Bolaget rapporterar en ökad förlust.
8/6/2020 2:00:46 PM - Heliospectra får order av Marcella Property värd 120 000 dollar - Heliospectra har mottagit en order från amerikanska Marcella Property Group till ett värde av 120 000 dollar, enligt ett pressmeddelande.